摘要
目的探讨抗肿瘤靶向药物利妥昔单抗(美罗华)不良反应的特点及规律,为临床安全、合理用药提供参考。方法采用回顾性研究方法,利用中国期刊全文数据库对1999～2009年报道的利妥昔单抗不良反应病例进行统计分析。结果不良反应主要为输注反应,且主要出现于第1次静脉滴注。结论使用利妥昔单抗治疗应严密监护,保证用药安全。
Objective To investigate the adverse reactions of rituximab（Rituxan and MabThera） in retrospection to provide references for safe and rational drug use clinically.Methods A retrospective analysis was conducted on adverse reactions of rituximab during the period from 1999 to 2009 retrieved from CNKI database.Results The main ADRs were infusion reactions,and occurred mainly in the first intravenous drip.Conclusion The use of rituximab treatment should be closely monitored to ensure the safety of drug use.
出处
《广东药学院学报》
CAS
2010年第2期179-181,共3页
Academic Journal of Guangdong College of Pharmacy
关键词
利妥昔单抗
美罗华
不良反应
rituximab
Rituxan and MabThera
adverse drug reactions
